研究者業績

高山 直也

Takayama Naoya  (Naoya Takayama)

基本情報

所属
千葉大学 大学院医学研究院 准教授

研究者番号
10584229
J-GLOBAL ID
201601019523177903
researchmap会員ID
B000261919

論文

 81
  • Sudip Kumar Paul, Motohiko Oshima, Ashwini Patil, Masamitsu Sone, Hisaya Kato, Yoshiro Maezawa, Hiyori Kaneko, Masaki Fukuyo, Bahityar Rahmutulla, Yasuo Ouchi, Kyoko Tsujimura, Mahito Nakanishi, Atsushi Kaneda, Atsushi Iwama, Koutaro Yokote, Koji Eto, Naoya Takayama
    Nature communications 15(1) 4772-4772 2024年6月10日  
    The underlying mechanisms of atherosclerosis, the second leading cause of death among Werner syndrome (WS) patients, are not fully understood. Here, we establish an in vitro co-culture system using macrophages (iMφs), vascular endothelial cells (iVECs), and vascular smooth muscle cells (iVSMCs) derived from induced pluripotent stem cells. In co-culture, WS-iMφs induces endothelial dysfunction in WS-iVECs and characteristics of the synthetic phenotype in WS-iVSMCs. Transcriptomics and open chromatin analysis reveal accelerated activation of type I interferon signaling and reduced chromatin accessibility of several transcriptional binding sites required for cellular homeostasis in WS-iMφs. Furthermore, the H3K9me3 levels show an inverse correlation with retrotransposable elements, and retrotransposable element-derived double-stranded RNA activates the DExH-box helicase 58 (DHX58)-dependent cytoplasmic RNA sensing pathway in WS-iMφs. Conversely, silencing type I interferon signaling in WS-iMφs rescues cell proliferation and suppresses cellular senescence and inflammation. These findings suggest that Mφ-specific inhibition of type I interferon signaling could be targeted to treat atherosclerosis in WS patients.
  • Si Jing Chen, Kazuya Hashimoto, Kosuke Fujio, Karin Hayashi, Sudip Kumar Paul, Akinori Yuzuriha, Wei-Yin Qiu, Emiri Nakamura, Maria Alejandra Kanashiro, Mio Kabata, Sou Nakamura, Naoshi Sugimoto, Atsushi Kaneda, Takuya Yamamoto, Hirohide Saito, Naoya Takayama, Koji Eto
    Nature Communications 15(1) 2024年3月22日  
    Abstract We recently achieved the first-in-human transfusion of induced pluripotent stem cell-derived platelets (iPSC-PLTs) as an alternative to standard transfusions, which are dependent on donors and therefore variable in supply. However, heterogeneity characterized by thrombopoiesis-biased or immune-biased megakaryocytes (MKs) continues to pose a bottleneck against the standardization of iPSC-PLT manufacturing. To address this problem, here we employ microRNA (miRNA) switch biotechnology to distinguish subpopulations of imMKCLs, the MK cell lines producing iPSC-PLTs. Upon miRNA switch-based screening, we find imMKCLs with lower let-7 activity exhibit an immune-skewed transcriptional signature. Notably, the low activity of let-7a-5p results in the upregulation of RAS like proto-oncogene B (RALB) expression, which is crucial for the lineage determination of immune-biased imMKCL subpopulations and leads to the activation of interferon-dependent signaling. The dysregulation of immune properties/subpopulations, along with the secretion of inflammatory cytokines, contributes to a decline in the quality of the whole imMKCL population.
  • 向井 務晃, 志賀 康浩, 江口 和, 水木 誉凡, 小坂 健太朗, 稲毛 一秀, 折田 純久, 高山 直也, 江藤 浩之, 大鳥 精司
    移植 58(3) 294-294 2023年12月  
  • 向井 務晃, 志賀 康浩, 江口 和, 新井 隆仁, 小坂 健太朗, 稲毛 一秀, 折田 純久, 高山 直也, 江藤 浩之, 大鳥 精司
    移植 58(3) 295-295 2023年12月  
  • 向井 務晃, 新井 隆仁, 志賀 康浩, 井上 雅寛, 稲毛 一秀, 折田 純久, 江口 和, 高山 直也, 江藤 浩之, 大鳥 精司
    移植 58(3) 299-299 2023年12月  

MISC

 36

共同研究・競争的資金等の研究課題

 6